ScreenerHero

NXTCLNextCell Pharma AB

STO · SE · Healthcare · Biotechnology · nextcellpharma.com
1.180SEK+7.27%Mkt Cap: 12.57M $P/E: —

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cel…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap12.57M $
Enterprise Value10.21M $
Revenue (TTM)884.14K $
Gross Profit156.00K $
Net Income (TTM)-3.76M $
Revenue/Share0.0070 USD
Last Price1.180 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees—
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.69
EV/Revenue11.54
P/S12.65
P/B2.41
EPS (TTM)-0.43
EPS (Forward)—
52W Range
0.630048% of range1.784
52W High1.784 SEK
52W Low0.6300 SEK
Profitability
Gross Margin16.38%
Oper. Margin-376.06%
EBITDA Margin0.00%
Profit Margin-395.19%
ROE-77.77%
ROA-61.57%
Growth
Revenue Growth-17.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.61M $
CapEx (TTM)7.93K $
FCF Margin—
FCF Yield—
Net Debt-3.09M $
Net Debt/EBITDA0.82
Balance Sheet
Debt/Equity—
Current Ratio4.90
Quick Ratio4.87
Book Value/Sh0.4350 SEK
Cash/Share0.2560 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.500 SEK
Upside (mean)+196.6%
Target Range3.500 SEK – 3.500 SEK
# Analysts1
Ownership
Shares Out.111.39M
Float100.06M
Insiders15.18%
Institutions21.04%
Technical
SMA 501.047 (+12.7%)
SMA 2001.096 (+7.6%)
Beta0.73
S&P 52W Chg18.16%
Avg Vol (30d)276.29K
Avg Vol (10d)389.50K
Technical Indicators
RSI (14)57.0
MACD0.0188
MACD Signal0.0050
MACD Hist.+0.0138
BB Upper1.207 SEK
BB Middle1.070 SEK
BB Lower0.9330 SEK
BB Width25.60%
ATR (14)0.1147 SEK
Vol Ratio (20d)1.85x